Company intelligence / Profile preview
Virionyx Corporation Limited
Auckland, Auckland, New Zealandvirionyx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's HIV drug PEHRG-214 reached Phase 2 clinical trials at Harvard Medical School. Their MIS416 drug for multiple sclerosis failed Phase 2B trials in 2017, showing no clinically meaningful benefit or statistical significance.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- AntibodiesMicroparticle immune response modifier
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Harvard Medical SchoolHauptman-Woodward Medical Research InstituteZeptoMetrix
Beyond the preview
Go deeper on Virionyx Corporation Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virionyx Corporation Limited.